Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

424
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
424
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

New Knowledge About Tissue Engineering Under Microgravity Conditions in Space and on Earth.

International journal of molecular sciences·2026
Same author

Genetic risk factor identification for common epilepsies guided by integrative omics data analysis.

Epilepsia·2025
Same author

Temporary effects of random positioning on the function and plasticity of proliferating monocytes.

Scientific reports·2025
Same author

The Effects of Microgravity on the Structure and Function of Cardiomyocytes.

Biomolecules·2025
Same author

Current Knowledge of the Impact of Vitamin D in Coronary Artery Disease.

International journal of molecular sciences·2025
Same author

Dynamic Mechanical Load as a Trigger for Growth and Proliferation in Porcine Epithelial Cells.

Biomolecules·2025

Video Experimental Relacionado

Updated: Jan 9, 2026

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

905

Conocimientos actuales sobre el aprocitentán en la hipertensión

Emilie Mathilde Bank-Mikkelsen1, Daniela Grimm1,2, Markus Wehland2

  • 1Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.

International journal of molecular sciences
|December 11, 2025
PubMed
Resumen
Este resumen es generado por máquina.

El aprocitentán (ACT) reduce eficazmente la presión arterial alta (hipertensión) en 14 días. Este antagonista dual de los receptores de endotelina muestra una promesa para el manejo de la hipertensión resistente sin efectos secundarios graves.

Palabras clave:
aprocitentánantagonista dual de los receptores de endotelinahipertensión

Más Videos Relacionados

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.0K
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

16.6K

Videos de Experimentos Relacionados

Last Updated: Jan 9, 2026

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

905
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.0K
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

16.6K

Área de la Ciencia:

  • Farmacología
  • Medicina Cardiovascular
  • Terapéutica Clínica

Sus antecedentes:

  • La hipertensión (HT) es un problema de salud mundial importante, que aumenta el riesgo de enfermedad cardiovascular (ECV).
  • La HT es un factor de riesgo modificable, que requiere nuevas estrategias terapéuticas.
  • El aumento de la esperanza de vida y las tasas de obesidad están exacerbando la carga mundial de la hipertensión.

Objetivo del estudio:

  • Revisar el conocimiento actual sobre el aprocitentán (ACT) para el manejo de la hipertensión.
  • Explorar los mecanismos farmacológicos y el potencial terapéutico del ACT.
  • Evaluar el papel del ACT en el abordaje de la hipertensión resistente.

Principales métodos:

  • Se realizó una búsqueda bibliográfica en PubMed y ClinicalTrials.gov.
  • Se utilizaron términos de búsqueda como "hipertensión", "aprocitentán", "presión arterial alta" y "enfermedad cardiovascular".
  • Se revisaron estudios en humanos y animales sobre la eficacia y seguridad del ACT.

Principales resultados:

  • El ACT demostró una reducción significativa de la presión arterial en 14 días en estudios en humanos y animales.
  • Se identificó la dosis efectiva óptima en 25 mg, sin efectos adversos graves notificados.
  • El ACT mostró compatibilidad con otros agentes antihipertensivos, a veces produciendo efectos sinérgicos.

Conclusiones:

  • El aprocitentán (ACT) es un prometedor antagonista dual de los receptores de endotelina para la hipertensión.
  • El ACT puede desempeñar un papel clave en el manejo de la hipertensión resistente debido a su mecanismo de acción único.
  • Su compatibilidad con las terapias existentes sugiere un potencial de uso combinado en casos complejos.